Cargando…
Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer
Pancreatic cancer is the fourth leading cause of death worldwide due to its poorest prognoses with a 7% 5-year survival rate. Eighty percent of pancreatic cancer patients relapse after chemotherapy and develop early metastasis and drug resistance. Resistance to nucleoside analog gemcitabine frequent...
Autores principales: | Tsai, Lung-Hung, Hsu, Kai-Wen, Chiang, Cheng-Ming, Yang, Hsiu-Ju, Liu, Yu-Huei, Yang, Shun-Fa, Peng, Pei-Hua, Cheng, Wei-Chung, Wu, Heng-Hsiung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576602/ https://www.ncbi.nlm.nih.gov/pubmed/33082357 http://dx.doi.org/10.1038/s41598-020-73659-z |
Ejemplares similares
-
Targeting interleukin-17 receptors
por: Lee, Wen-Hwa, et al.
Publicado: (2015) -
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation
por: Pan, Yi-Ru, et al.
Publicado: (2023) -
Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin
por: Bafna, S, et al.
Publicado: (2009) -
Association of Serum T cell Immunoglobulin Domain and Mucin-3 and Interleukin-17 with Systemic Lupus Erythematosus
por: Jin, Lairun, et al.
Publicado: (2018) -
Stromal BMP signaling regulates mucin production in the large intestine via interleukin-1/17
por: Wang, Yalong, et al.
Publicado: (2023)